Lispro insulin as premeal therapy in type 1 diabetes: Comparison with Humulin R

New Zealand Medical Journal

Volumn 110, Issue 1056, 1997, Pages 435-438

  Daniels, André R ^a   Bruce, Raymond ^a,b   McGregor, Lillian ^a  

^a MIDDLEMORE HOSPITAL   (New Zealand)

^b HUTT HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN LISPRO; ISOPHANE INSULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BACKACHE; BLOOD GLUCOSE MONITORING; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PARESTHESIA; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; CHILD; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; MALE; MIDDLE AGED;

EID: 0030817780     PISSN: 00288446     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Bhaskar, Chou MCY, Field JB. Time-action characteristics of regular and NPH insulin in insulin-treated diabetics. J Clin Endocrinol Metab 1980; 50: 475-9.
2. Kinmouth AL, Baum JD. Timing of prebreakfast insulin injection and postprandial metabolic control in diabetic children. BMJ 1980; 280: 604-6.
3. Wang SR, Chase HP, Carg SK, et al. The effect of sugar cereal with and without a mixed meal on glycaemic response in children with diabetes. J Pediatr Gastroenterol Nutr 1991; 13: 155-60.
4. Dimitriadis GD, Gerich JE. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care 1983; 6: 374-7.
5. Lean MJE, NG LL, Tennison BR. Interval between insulin injection and eating in relation to blood glucose control in adult diabetics. BMJ 1985; 290: 105-8.
6. The DCCT Research Group. The effects of intensive insulin treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
7. Brems DN, Alter LA, Beckage MJ, et al. Altering the association properties of insulin by amino acid replacement. Prot Eng 1995; 5: 527-33.
8. Brange J, Owens D, Kang S, Vølund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990; 13: 923-54.
9. Heinemann L, Starke AAR, Heding L, Jensen I, Bermer M. Action profiles of fast onset insulin analogues. Diabetologia 1990; 33: 384-6.
10. B28) on meal-related plasma glucose excursions in type 1 diabetic subjects. Diabetes Care 1991; 14: 571-7.
11. Howey CH, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin: a rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396-402.
12. Trautmann ME. Effect of the insulin analogue [LYS(B28), PRO(B29)] on blood glucose control. Horm Metab Res 1994; 26: 588-90.
13. DiMarchi RD, Chance RE, Long HB, et al. Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor-I. Horm Res 1994; 41(Suppl 2): 93-6.
14. DiMarchi RD, Mayer JP, Fan L, et al. Synthesis of a fast acting insulin based on structural homology with insulin-like growth factor-I. In: Smith JA, Rivier JE, editors, Peptides: Chemistry and Biology. Proceedings of the Twelfth American Peptide-Symposium; Leiden, Netherlands: ESCOM; 1992. p26-8.
15. B29 -human insulin. Structure 1995; 3: 615-22.
16. Torlone E, Fanelli C, Rambotti AM, et al. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM. Diabetologia 1994; 37: 713-20.
17. Tuominen JA, Karonen S-L, Melamies L, et al. Exercise-induced hypoglycaemia in IDDM patients treated with a short acting insulin analogue. Diabetologia 1995; 38: 106-11.
18. Barnett A, Owens D. Insulin analogues. Lancet 1997; 349: 47-51.
19. Andersen J, Brunelle RL, Koivisto VA, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment Multicenter Insulin Lispro Study Group. Diabetes 1997; 46; 265-70.
20. World Health Organization. WHO Expert Committee on diabetes mellitus. Second Report. Geneva: WHO, Technical Report Series No 646; 1980.
21. Garg SK, Carmain JA, Braddy KC, et al. Pre-meal insulin analogue insulin Lispro vs Humulin R insulin treatment in young subjects with type 1 diabetes. Diabet Med 1996; 13: 47-52.
22. Burge MR, Castillo KR, Schade DS. Meal composition is a determinant of Lispro-induced hypoglycaemia in IDDM. Diabetes Care 1997; 20: 152-5.
23. Burge MR, Waters DL. Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 920-4.
24. Torlone E, Pampanelli S, Lalli, C, et al. Effects of short-acting insulin analog [LYS(B28), PRC(B29)] on postprandial blood glucose control in IDDM. Diabetes Care 1996; 19: 945-52.
25. Galloway JA, Chance RE. Improving insulin therapy: Achievements and challenges. Horm Metab Res 1994; 26: 591-8.